{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Number of participants who, after therapy, had more of the differentiated types of blood (red cells, platelets, and white cells) compared to abnormal bone marrow cells than before therapy","groups":[{"description":"INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \\< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.\n\nflow cytometry: Correlative studies\n\nDNA methylation analysis: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ndecitabine: Given subcutaneously\n\nmicroarray analysis: Correlative studies\n\ngene expression analysis: Correlative studies\n\npharmacological study: Correlative studies\n\npolymorphism analysis: Correlative studies","id":"OG000","title":"Arm I: Decitabine 0.2mg/kg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 weeks after treatment","title":"Proportion of Patients With Bone Marrow Evidence of Terminal Differentiation Response to Therapy.","type":"SECONDARY","unitOfMeasure":"participants"}